Alprazolam for essential tremor

Elisa Bruno, Alessandra Nicoletti, Graziella Quattrocchi, Graziella Filippini, Mario Zappia, Carlo Colosimo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: Essential tremor (ET) is one of the most common movement disorders. Treatment is based primarily on pharmacological agents. On this basis, although primidone and propranolol are well-established treatments in clinical practice, they could be ineffective in 25% to 55% of patients and can produce serious adverse events (AEs) in a large percentage of individuals. For these reasons, evaluating treatment alternatives for ET may be a worthwhile pursuit. Alprazolam has been suggested as a potentially useful agent for treatment of individuals with ET, but its efficacy and safety are uncertain.

OBJECTIVES: PrimaryTo assess the efficacy and safety of alprazolam in the treatment of individuals with ET. SecondaryTo examine effects of alprazolam treatment on the quality of life of people with ET.

SEARCH METHODS: We carried out a systematic search without language restrictions to identify all relevant trials. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January 1966 to September 2015), EMBASE (January 1988 to September 2015), the National Institute for Health and Care Excellence (NICE) (1999 to September 2015), ClinicalTrials.gov (1997 to September 2015) and the World Health Organiza tion (WHO) International Clinical Trials Registry Platform (ICTRP) (2004 to September 2015). We handsearched grey literature and examined the reference lists of identified studies and reviews.

SELECTION CRITERIA: We included all randomised controlled trials (RCTs) of alprazolam versus placebo or any other treatment. We included studies in which ET was diagnosed according to accepted and validated diagnostic criteria. We excluded studies that included patients presenting with secondary forms of tremor or reporting only neurophysiological parameters for the pur p ose of assessing outcomes.

DATA COLLECTION AND ANALYSIS: Two review authors independently collected and extracted data using a data collection form. We assessed risk of bias and the body of evidence. We used inverse variance methods for continuous outcomes and measurement scales. We compared differences between treatment groups as mean differences. We used Review Manager software for management and analysis of data.

MAIN RESULTS: We included in this review one trial that compared alprazolam versus placebo (24 participants). It was judged to have high overall risk of bias. We graded the overall quality of evidence as very low. Compared with those given placebo, participants treated with alprazolam showed a significant reduction in tremor severity (mean difference (MD) -0.75, 95% confidence interval (CI) -0.83 to -0.67). Nine alprazolam-treated participants (75%) developed AEs, mainly represented by sedation (50%), constipation (17%) and dry mouth (9%). No participants in the alprazolam group and no p articipants in the placebo group discontinued treatment and dropped out of the study.

AUTHORS' CONCLUSIONS: Currently available data reveal evidence insufficient for assessment of the efficacy and safety of alprazolam treatment for individuals with ET.

Original languageEnglish
Pages (from-to)CD009681
JournalThe Cochrane database of systematic reviews
Volume12
DOIs
Publication statusPublished - 2015

Fingerprint

Alprazolam
Essential Tremor
Placebos
Therapeutics
Tremor
Safety
Primidone
Literature
Movement Disorders
National Institutes of Health (U.S.)
Constipation
Propranolol
MEDLINE
Registries
Mouth
Language
Software
Quality of Life
Clinical Trials
Pharmacology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bruno, E., Nicoletti, A., Quattrocchi, G., Filippini, G., Zappia, M., & Colosimo, C. (2015). Alprazolam for essential tremor. The Cochrane database of systematic reviews, 12, CD009681. https://doi.org/10.1002/14651858.CD009681.pub2

Alprazolam for essential tremor. / Bruno, Elisa; Nicoletti, Alessandra; Quattrocchi, Graziella; Filippini, Graziella; Zappia, Mario; Colosimo, Carlo.

In: The Cochrane database of systematic reviews, Vol. 12, 2015, p. CD009681.

Research output: Contribution to journalArticle

Bruno, E, Nicoletti, A, Quattrocchi, G, Filippini, G, Zappia, M & Colosimo, C 2015, 'Alprazolam for essential tremor', The Cochrane database of systematic reviews, vol. 12, pp. CD009681. https://doi.org/10.1002/14651858.CD009681.pub2
Bruno E, Nicoletti A, Quattrocchi G, Filippini G, Zappia M, Colosimo C. Alprazolam for essential tremor. The Cochrane database of systematic reviews. 2015;12:CD009681. https://doi.org/10.1002/14651858.CD009681.pub2
Bruno, Elisa ; Nicoletti, Alessandra ; Quattrocchi, Graziella ; Filippini, Graziella ; Zappia, Mario ; Colosimo, Carlo. / Alprazolam for essential tremor. In: The Cochrane database of systematic reviews. 2015 ; Vol. 12. pp. CD009681.
@article{420432aae9bf424589fdc2d34d0b834b,
title = "Alprazolam for essential tremor",
abstract = "BACKGROUND: Essential tremor (ET) is one of the most common movement disorders. Treatment is based primarily on pharmacological agents. On this basis, although primidone and propranolol are well-established treatments in clinical practice, they could be ineffective in 25{\%} to 55{\%} of patients and can produce serious adverse events (AEs) in a large percentage of individuals. For these reasons, evaluating treatment alternatives for ET may be a worthwhile pursuit. Alprazolam has been suggested as a potentially useful agent for treatment of individuals with ET, but its efficacy and safety are uncertain.OBJECTIVES: PrimaryTo assess the efficacy and safety of alprazolam in the treatment of individuals with ET. SecondaryTo examine effects of alprazolam treatment on the quality of life of people with ET.SEARCH METHODS: We carried out a systematic search without language restrictions to identify all relevant trials. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January 1966 to September 2015), EMBASE (January 1988 to September 2015), the National Institute for Health and Care Excellence (NICE) (1999 to September 2015), ClinicalTrials.gov (1997 to September 2015) and the World Health Organiza tion (WHO) International Clinical Trials Registry Platform (ICTRP) (2004 to September 2015). We handsearched grey literature and examined the reference lists of identified studies and reviews.SELECTION CRITERIA: We included all randomised controlled trials (RCTs) of alprazolam versus placebo or any other treatment. We included studies in which ET was diagnosed according to accepted and validated diagnostic criteria. We excluded studies that included patients presenting with secondary forms of tremor or reporting only neurophysiological parameters for the pur p ose of assessing outcomes.DATA COLLECTION AND ANALYSIS: Two review authors independently collected and extracted data using a data collection form. We assessed risk of bias and the body of evidence. We used inverse variance methods for continuous outcomes and measurement scales. We compared differences between treatment groups as mean differences. We used Review Manager software for management and analysis of data.MAIN RESULTS: We included in this review one trial that compared alprazolam versus placebo (24 participants). It was judged to have high overall risk of bias. We graded the overall quality of evidence as very low. Compared with those given placebo, participants treated with alprazolam showed a significant reduction in tremor severity (mean difference (MD) -0.75, 95{\%} confidence interval (CI) -0.83 to -0.67). Nine alprazolam-treated participants (75{\%}) developed AEs, mainly represented by sedation (50{\%}), constipation (17{\%}) and dry mouth (9{\%}). No participants in the alprazolam group and no p articipants in the placebo group discontinued treatment and dropped out of the study.AUTHORS' CONCLUSIONS: Currently available data reveal evidence insufficient for assessment of the efficacy and safety of alprazolam treatment for individuals with ET.",
author = "Elisa Bruno and Alessandra Nicoletti and Graziella Quattrocchi and Graziella Filippini and Mario Zappia and Carlo Colosimo",
year = "2015",
doi = "10.1002/14651858.CD009681.pub2",
language = "English",
volume = "12",
pages = "CD009681",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Alprazolam for essential tremor

AU - Bruno, Elisa

AU - Nicoletti, Alessandra

AU - Quattrocchi, Graziella

AU - Filippini, Graziella

AU - Zappia, Mario

AU - Colosimo, Carlo

PY - 2015

Y1 - 2015

N2 - BACKGROUND: Essential tremor (ET) is one of the most common movement disorders. Treatment is based primarily on pharmacological agents. On this basis, although primidone and propranolol are well-established treatments in clinical practice, they could be ineffective in 25% to 55% of patients and can produce serious adverse events (AEs) in a large percentage of individuals. For these reasons, evaluating treatment alternatives for ET may be a worthwhile pursuit. Alprazolam has been suggested as a potentially useful agent for treatment of individuals with ET, but its efficacy and safety are uncertain.OBJECTIVES: PrimaryTo assess the efficacy and safety of alprazolam in the treatment of individuals with ET. SecondaryTo examine effects of alprazolam treatment on the quality of life of people with ET.SEARCH METHODS: We carried out a systematic search without language restrictions to identify all relevant trials. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January 1966 to September 2015), EMBASE (January 1988 to September 2015), the National Institute for Health and Care Excellence (NICE) (1999 to September 2015), ClinicalTrials.gov (1997 to September 2015) and the World Health Organiza tion (WHO) International Clinical Trials Registry Platform (ICTRP) (2004 to September 2015). We handsearched grey literature and examined the reference lists of identified studies and reviews.SELECTION CRITERIA: We included all randomised controlled trials (RCTs) of alprazolam versus placebo or any other treatment. We included studies in which ET was diagnosed according to accepted and validated diagnostic criteria. We excluded studies that included patients presenting with secondary forms of tremor or reporting only neurophysiological parameters for the pur p ose of assessing outcomes.DATA COLLECTION AND ANALYSIS: Two review authors independently collected and extracted data using a data collection form. We assessed risk of bias and the body of evidence. We used inverse variance methods for continuous outcomes and measurement scales. We compared differences between treatment groups as mean differences. We used Review Manager software for management and analysis of data.MAIN RESULTS: We included in this review one trial that compared alprazolam versus placebo (24 participants). It was judged to have high overall risk of bias. We graded the overall quality of evidence as very low. Compared with those given placebo, participants treated with alprazolam showed a significant reduction in tremor severity (mean difference (MD) -0.75, 95% confidence interval (CI) -0.83 to -0.67). Nine alprazolam-treated participants (75%) developed AEs, mainly represented by sedation (50%), constipation (17%) and dry mouth (9%). No participants in the alprazolam group and no p articipants in the placebo group discontinued treatment and dropped out of the study.AUTHORS' CONCLUSIONS: Currently available data reveal evidence insufficient for assessment of the efficacy and safety of alprazolam treatment for individuals with ET.

AB - BACKGROUND: Essential tremor (ET) is one of the most common movement disorders. Treatment is based primarily on pharmacological agents. On this basis, although primidone and propranolol are well-established treatments in clinical practice, they could be ineffective in 25% to 55% of patients and can produce serious adverse events (AEs) in a large percentage of individuals. For these reasons, evaluating treatment alternatives for ET may be a worthwhile pursuit. Alprazolam has been suggested as a potentially useful agent for treatment of individuals with ET, but its efficacy and safety are uncertain.OBJECTIVES: PrimaryTo assess the efficacy and safety of alprazolam in the treatment of individuals with ET. SecondaryTo examine effects of alprazolam treatment on the quality of life of people with ET.SEARCH METHODS: We carried out a systematic search without language restrictions to identify all relevant trials. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January 1966 to September 2015), EMBASE (January 1988 to September 2015), the National Institute for Health and Care Excellence (NICE) (1999 to September 2015), ClinicalTrials.gov (1997 to September 2015) and the World Health Organiza tion (WHO) International Clinical Trials Registry Platform (ICTRP) (2004 to September 2015). We handsearched grey literature and examined the reference lists of identified studies and reviews.SELECTION CRITERIA: We included all randomised controlled trials (RCTs) of alprazolam versus placebo or any other treatment. We included studies in which ET was diagnosed according to accepted and validated diagnostic criteria. We excluded studies that included patients presenting with secondary forms of tremor or reporting only neurophysiological parameters for the pur p ose of assessing outcomes.DATA COLLECTION AND ANALYSIS: Two review authors independently collected and extracted data using a data collection form. We assessed risk of bias and the body of evidence. We used inverse variance methods for continuous outcomes and measurement scales. We compared differences between treatment groups as mean differences. We used Review Manager software for management and analysis of data.MAIN RESULTS: We included in this review one trial that compared alprazolam versus placebo (24 participants). It was judged to have high overall risk of bias. We graded the overall quality of evidence as very low. Compared with those given placebo, participants treated with alprazolam showed a significant reduction in tremor severity (mean difference (MD) -0.75, 95% confidence interval (CI) -0.83 to -0.67). Nine alprazolam-treated participants (75%) developed AEs, mainly represented by sedation (50%), constipation (17%) and dry mouth (9%). No participants in the alprazolam group and no p articipants in the placebo group discontinued treatment and dropped out of the study.AUTHORS' CONCLUSIONS: Currently available data reveal evidence insufficient for assessment of the efficacy and safety of alprazolam treatment for individuals with ET.

UR - http://www.scopus.com/inward/record.url?scp=84965188360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965188360&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD009681.pub2

DO - 10.1002/14651858.CD009681.pub2

M3 - Article

C2 - 26638213

AN - SCOPUS:84965188360

VL - 12

SP - CD009681

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1361-6137

ER -